Medicare. It's a term synonymous with retirement. While this national umbrella of
health insurance and social security aid may seem like a straight-forward
government implementation for our elderly, it doesn't take much work to figure
out that it is not straightforward at all. Deductibles, coverage gaps, third-party
copays, and part A through D separation are just some of the terminology that
our senior citizens have to navigate to ensure that their insurance plan, or
plans, are functioning optimally. There is however, an overlooked truth that
plays a key role in Medicare's prescription coverage: Medicare spending reflects
real-world events. As the title states, this analysis is an effort to
conceptualize how real-world events impact Medicare's spending on prescription
drugs. In this analysis, we are going to look a particular medication, whose
"mainstream" (more specifically conservative mainstream) coverage affected Medicare prescription spending:
Ivermectin. More specifically, we'll be looking at the
total dollar amount spend by Medicare Part D on Ivermectin from 2017 to 2021,
as well as the total amount of prescriptions written and submitted through a
patient's Medicare Part D (referred to as a "claim").
# In this chunk of code, we are selecting the columns that are pertinent to our investigation: Total Medicare Spending, and Total Claims from Years 2017 and 2021. We are also calling any package from our library which we will be using for our visualization.
library(tidyverse)
## ── Attaching packages ─────────────────────────────────────── tidyverse 1.3.2 ──
## ✔ ggplot2 3.4.1 ✔ purrr 1.0.1
## ✔ tibble 3.1.8 ✔ dplyr 1.1.0
## ✔ tidyr 1.3.0 ✔ stringr 1.5.0
## ✔ readr 2.1.3 ✔ forcats 1.0.0
## ── Conflicts ────────────────────────────────────────── tidyverse_conflicts() ──
## ✖ dplyr::filter() masks stats::filter()
## ✖ dplyr::lag() masks stats::lag()
library(scales)
##
## Attaching package: 'scales'
##
## The following object is masked from 'package:purrr':
##
## discard
##
## The following object is masked from 'package:readr':
##
## col_factor
library(ggplot2)
MPartD <- read_csv("MedicarePartDSpending.csv")
## Rows: 13751 Columns: 46
## ── Column specification ────────────────────────────────────────────────────────
## Delimiter: ","
## chr (3): Brnd_Name, Gnrc_Name, Mftr_Name
## dbl (43): Tot_Mftr, Tot_Spndng_2017, Tot_Dsg_Unts_2017, Tot_Clms_2017, Tot_B...
##
## ℹ Use `spec()` to retrieve the full column specification for this data.
## ℹ Specify the column types or set `show_col_types = FALSE` to quiet this message.
MPartD <- MPartD %>% select(c(Brnd_Name, Gnrc_Name, Mftr_Name, Tot_Spndng_2017, Tot_Spndng_2018, Tot_Spndng_2019, Tot_Spndng_2020, Tot_Spndng_2021, Tot_Clms_2017, Tot_Clms_2018, Tot_Clms_2019, Tot_Clms_2020, Tot_Clms_2021))
glimpse(MPartD)
## Rows: 13,751
## Columns: 13
## $ Brnd_Name <chr> "1st Tier Unifine Pentips", "1st Tier Unifine Pentips"…
## $ Gnrc_Name <chr> "Pen Needle, Diabetic", "Pen Needle, Diabetic", "Pen N…
## $ Mftr_Name <chr> "Overall", "Owen Mumford Us", "Overall", "Owen Mumford…
## $ Tot_Spndng_2017 <dbl> 217938.04, 217938.04, 402124.68, 402124.68, 13386250.0…
## $ Tot_Spndng_2018 <dbl> 167193.78, 167193.78, 369402.85, 369402.85, 10685287.6…
## $ Tot_Spndng_2019 <dbl> 139201.68, 139201.68, 343031.42, 343031.42, 10126697.3…
## $ Tot_Spndng_2020 <dbl> 118923.24, 118923.24, 210217.15, 210217.15, 9202476.64…
## $ Tot_Spndng_2021 <dbl> 102280.76, 102280.76, 131927.33, 131927.33, 7038593.83…
## $ Tot_Clms_2017 <dbl> 8595, 8595, 15403, 15403, 48283, NA, 55, 2017, 5744, 2…
## $ Tot_Clms_2018 <dbl> 6538, 6538, 14931, 14931, 40513, 832, 82, 125, 5307, 1…
## $ Tot_Clms_2019 <dbl> 5392, 5392, 14581, 14581, 42694, 3311, 44, 21, 7984, 1…
## $ Tot_Clms_2020 <dbl> 4457, 4457, 8408, 8408, 37136, 3347, 17, 17, 6225, 109…
## $ Tot_Clms_2021 <dbl> 3708, 3708, 4564, 4564, 30540, 3276, 39, 13, 4154, 966…
knitr:: include_graphics("/Users/ibrahim/Desktop/ivercollage.jpeg")
This is a collage of various news outlets and Medicinal Journals that have analyzed or performed studies on Ivermectin and its effects as a Sars-Covid-19 prophylactic (a drug intended to prevent disease).
Ivermectin in tablet form is a medication intended to be used as an anti-parasite.
The FDA today only recognizes Ivermectin (in tablet form) for the treatment of Strongyloidiasis, and Onchocerciasis, both of which are infections caused by
parasitic worms. In June 2020, a group of Australian researchers published a
paper claiming that large doses of Ivermectin could essentially, stop the
coronavirus from replicating in cell cultures. This quickly spread like wildfire,
more specifically, among the skeptics and anti-vaccination community. In early 2021,
doctors began prescribing Ivermectin to anyone who asked. The problem was,
that at a dose necessary to (potentially) stop the virus, it's bound to do more
harm than good. I myself, working at Walgreens as a pharmacy technician at the
time, saw an overwhelming amount of Ivermectin prescriptions come to the pharmacy,
most of which, were denied by insurance. There were however, plenty of Medicare
claims that were processed, which brings us to the bigger picture.
# Here we are filtering to observe only Ivermectin spending, and condensing the names of the columns to its appropriate year of spending for 3 of the manufacturers that received the largest payouts from Medicare Part D for Ivermectin.
Iver <- MPartD %>% select(!c(Brnd_Name)) %>% filter(Gnrc_Name == "IVermectin") %>% slice(c(2, 6, 10))
IverSpend <- Iver %>% select(c(Mftr_Name, Tot_Spndng_2017, Tot_Spndng_2018, Tot_Spndng_2019, Tot_Spndng_2020, Tot_Spndng_2021)) %>% rename("2017" = "Tot_Spndng_2017", "2018" = "Tot_Spndng_2018", "2019" = "Tot_Spndng_2019", "2020" = "Tot_Spndng_2020", "2021" = "Tot_Spndng_2021")
# Here we are reformatting the data, and creating our visualization
IverSpndLong <- tidyr::gather(IverSpend, key = "Date", value = "Count", -Mftr_Name) %>% filter(!is.na(Count)) %>% arrange(Mftr_Name)
IverSpendGraph <-ggplot(IverSpndLong, aes(x = Date, y = Count, fill = Mftr_Name)) +
geom_col(position = "dodge") +
geom_text(data = subset(IverSpndLong, Mftr_Name == "Merck Sharp & D"),
aes(label = Count), position = position_dodge(width = 0.9), size = 2.5) +
ggtitle("Medicare Part D Spending on Ivermectin by Manufacturer") +
theme_minimal() +
xlab("Year") +
ylab("Dollars Spent") +
labs(caption = "* Values provided are for Merck Sharp & D, which are relatively small *", fill = "Manufacturer Name") +
scale_y_continuous(breaks = seq(0, 20000000, by = 1000000),
labels = scales::comma)
IverSpendGraph
# Here we are doing the same as with the Ivermectin spending report, but with the total quantities of prescriptions submitted through Medicare Part D
IverClaims <- MPartD %>% select(!c(Brnd_Name)) %>% filter(Gnrc_Name == "IVermectin") %>% select(c(Mftr_Name, Tot_Clms_2017, Tot_Clms_2018, Tot_Clms_2019, Tot_Clms_2020, Tot_Clms_2021)) %>% rename("2017" = "Tot_Clms_2017", "2018" = "Tot_Clms_2018", "2019" = "Tot_Clms_2019", "2020" = "Tot_Clms_2020", "2021" = "Tot_Clms_2021") %>% slice(c(2, 6, 10))
IverClaimsLong <- tidyr::gather(IverClaims, key = "Date", value = "Count", -Mftr_Name) %>% filter(!is.na(Count)) %>% arrange(Mftr_Name)
view(IverClaimsLong)
# Here we are visualizing total claims
IverClmsGraph <- ggplot(IverClaimsLong, aes(x = Date, y = Count, fill = Mftr_Name)) +
geom_col(position = "dodge") +
labs(title = "Total Amount of Ivermectin Claims by Manufacturer",
x = "Year",
y = "Number of Claims",
fill = "Manufacturer Name") +
scale_y_continuous(breaks = seq(0, 250000, by = 10000),
labels = scales::comma) +
geom_text(aes(label = scales::comma(Count)),
position = position_dodge(width = 0.9),
size = 2,
vjust = -1)
IverClmsGraph
The results, while astounding, still have a lot of grey area. We can see enormous jumps
going into the years of 2020 and 2021 by the three manufacturers that had the largest
claims, and Medicare Part D payouts. What this means is that not only did Medicare
patients jump into the Ivermectin wave, but also that Medicare was paying for these prescriptions. More than just a discovery, it's an opportunity. An opportunity to open
up the conversation about our geriatric comminunity and Medicare practices. Clearly
these claims were processed, submitted, dispensed, and payed out. Was it a jump to a
commercialized pharmaceutical industry? Or rather, was it something more sinister?
The world of phamracy, and pharmaceuticals has never been, and will never be
straightforward. As I stated, there are plenty of loopholes that our capitalist,
for-profit nation has found that affect the accuracy of investigations like these.
I'll provide an example: There were many insurances that were cracking down on the
"Ivermectin Craze", Medicare Part D included. These insurances were denying
prescription coverage on Ivermectin claims that appeared to have been
inappropriately written for the non-FDA approved treamtent of Covid-19. When
this happens, patients have two options: Ask their provider to petition for the
medication to be covered by calling the insurance company, or simply pay out of
pocket (cash price) for the medication with no insurance. If the patients did this,
it's as if there was no prescription under Medicare Part D to begin with,
affecting accuracy on multiple levels. So we have many, possibly thousands of
prescriptions that flew under the radar. We are however, able to work with
what we have.